CRISPR Therapeutics, Nkarta partner on gene edited cancer therapies

By The Science Advisory Board staff writers

May 7, 2021 -- CRISPR Therapeutics has established a strategic partnership with Nkarta to research, develop, and commercialize CRISPR/Cas9 gene edited cell therapies for cancer.

Under the agreement, the companies will co-develop and co-commercialize two chimeric antigen receptor (CAR) natural killer (NK) cell product candidates: one that targets the CD70 tumor antigen and the other will be determined later.

Moreover, they will combine cell therapy engineering and manufacturing capabilities to advance the development of a novel NKT-cell product candidate targeting both the adaptive and innate immune systems. Lastly, Nkarta will obtain a license to CRISPR gene editing technology to edit five gene targets in an unlimited number of its own NK cell therapy products.

CRISPR Therapeutics and Nkarta will equally share all research and development costs and profits related to the collaboration. For each noncollaboration product candidate incorporating a gene editing target licensed from CRISPR Therapeutics, Nkarta will retain worldwide rights and pay CRISPR Therapeutics milestone and royalties on net sales.

The agreement includes a three-year exclusivity period between the companies covering research, development, and commercialization of allogeneic, gene edited, donor-derived NK cells and NKT cells.

Financial details of the collaboration were not disclosed.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.